Astana Biomed Group, an authorized Abcam distributor in Central Asia

Anti-CD3 epsilon antibody [PC3/188A] - BSA and Azide free (ab269766)

Key features and details

  • Mouse monoclonal [PC3/188A] to CD3 epsilon - BSA and Azide free
  • Suitable for: IHC-P
  • Reacts with: Human
  • Isotype: IgG1

Overview

  • Product name

    Anti-CD3 epsilon antibody [PC3/188A] - BSA and Azide free
    See all CD3 epsilon primary antibodies

  • Description

    Mouse monoclonal [PC3/188A] to CD3 epsilon - BSA and Azide free

  • Host species

    Mouse

  • Tested Applications & Species

    Application Species
    IHC-P
    Human
    See all applications and species data

  • Immunogen

    Synthetic peptide corresponding to Human CD3 epsilon aa 150 to the C-terminus. Cytoplasmic domain.
    Database link: P07766

    Run BLAST with BLAST the sequence with ExPASy Run BLAST with BLAST the sequence with NCBI

  • Positive control

    • IHC-P: Human tonsil tissue.

  • General notes

    ab269766 is a carrier free version of ab219328. This format is designed for use in antibody labeling, including fluorochromes, metal isotypes, oligonucleotides, enzymes.

     

Properties

Images

  • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CD3 epsilon antibody [PC3/188A] - BSA and Azide free (ab269766)
    Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CD3 epsilon antibody [PC3/188A] - BSA and Azide free (ab269766)

    Immunohistochemical analysis of formalin-fixed paraffin-embedded human tonsil tissue sections labeling CD3 epsilon with ab219328 at 2 µg/mL.

    This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab219328).

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Alternative products to Anti-CD3 epsilon antibody [PC3/188A] - BSA and Azide free (ab269766)

© 2021 Astana Biomed Group LLP. All rights reserved.